ClinicalTrials.gg
CompletedNCT03557281Updated Oct 26, 2023Results posted

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

A Phase 2 interventional study of GSK3036656 and Rifafour e-275 in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's title name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
51st of 67
76 · median 122
Started
2019
with 3 others
Phase 2
49 of 78
8 open now
Registered
33rd of 78
by date

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 51st largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2019, is one of 49 in phase 2, and was the 33rd registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

Tuberculosis remains a concerning health problem, with Mycobacterium Tuberculosis (MTB) now causing more deaths than acquired immune deficiency syndrome (AIDS). GSK3036656 is a compound with a novel mechanism of action under development for the treatment of tuberculosis. It suppresses protein synthesis in MTB by selectively inhibiting the enzyme Leucyl t-ribose nucleic acid (RNA) synthetase. Thus, this study will investigate the early bactericidal activity, safety and tolerability of GSK3036656 in up to four sequential cohorts of subjects with rifampicin-susceptible tuberculosis. The primary objective of this dose-escalation study is to establish the anti-tuberculosis effect of GSK3036656 on serial colony forming units (CFU) counts of MTB in sputum over 14 days of therapy. Subjects in each cohort will be randomized in 3:1 ratio to one of two treatments: either GSK3036656 or standard-of-care (RIFAFOUR® e-275) regimen. The approximate duration of the study for an individual subject will be 5 weeks, including 1 week of screening, 2 weeks of treatment period and another 2 weeks of final follow-up visit. RIFAFOUR e-275 is a registered trademark of Sanofi-Aventis.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Early bactericidal activity
  • Mycobacterium Tuberculosis
  • GSK3036656
  • Pulmonary tuberculosis
  • Colony forming units
04

In context

Tuberculosis, Pulmonary Reclassified

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

This study's enrollment of 76 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be 18 to 65 years of age inclusive, at the time of signing the .
  • In addition, subjects recruited into cohorts that are planned to undergo fluorodeoxyglucose (FDG) positron emission tomography/ Computed Tomography (PET/CT) must be >=25 years of age, at the time of signing the informed consent.
  • New episode of untreated, rifampicin-susceptible pulmonary tuberculosis.
  • A chest X-ray picture which in the opinion of the Investigator is consistent with tuberculosis.
  • At least one sputum sample positive on direct microscopy for acid-fast bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease/ World Health Organization [IUATLD/WHO] scale) or molecular test (Xpert MTB/ rifampicin) with result of either medium or high positive for MTB: Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 milliliter or more); estimated from a spot sputum sample at screening; confirmed at the first overnight collection; if less than 10 milliliter is collected overnight this may be repeated once.
  • Normal echocardiogram or echocardiogram with normal left ventricular function with at most trace to mild valvular regurgitation and no valvular stenosis.
  • Within the normal range for the assay for troponin and b-type natriuretic peptide at screening.
  • Body weight (in light clothing and with no shoes) between 40 and 90 kilograms, inclusive, at screening.
  • Male or female of non- will be included in the study. A male subject with female partners of child-bearing potential must agree to use during the treatment period and for at least 6 weeks, corresponding to time needed to eliminate study treatment plus an additional 90 days (a spermatogenesis cycle) for study treatments with teratogenic potential after the last dose of study treatment and refrain from donating sperm during this period. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Pre-menopausal females with one of the following; documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or documented bilateral salpingectomy; hysterectomy; documented Bilateral Oophorectomy. will be defined as 12 months of spontaneous amenorrhea without an alternative medical cause. Post-menopausal status will be confirmed by a simultaneous follicle-stimulating hormone and estradiol levels test.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Evidence of a (as judged by the Investigator) condition or abnormality (other than the indication being studied) that might compromise safety or the interpretation of trial efficacy or safety endpoints.
  • Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator.
  • A previous episode of treated tuberculosis less than 3 years ago.
  • Clinically significant evidence of extrathoracic tuberculosis (miliary tuberculosis, abdominal tuberculosis, urogenital tuberculosis, osteoarthritic tuberculosis, tuberculosis meningitis), as judged by the Investigator.
  • Interval > 450 milliseconds.
  • History of allergy to any of the trial product/s or related substances as confirmed by the clinical judgement of the Investigator.
  • History of photosensitivity.
  • Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the subject.
  • infected subjects: having a cluster of differentiation 4+ (CD4+) count \<350 cells per microliter; or having received antiretroviral therapy medication within the last 90 days; or having received oral or intravenous antifungal medication within the last 90 days; or with an AIDS-defining opportunistic infection or (except pulmonary tuberculosis).
  • Participated in other clinical studies with investigational agents within 8 weeks prior to the first dosing day in the current study.
  • Subjects with diabetes (Type 1 or 2), point of care above 6.5 millimoles per mole, or random glucose over 11.1 millimoles per liter will be excluded from cohorts undergoing FDGPET/CT. Subjects not undergoing FDG-PET/CT will be excluded if they have unstable diabetes or insulin dependency.
  • Treatment received with any drug active against MTB (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole), or with medications such as tumor necrosis factor -alpha inhibitors or systemic or inhaled , within 2 weeks prior to screening.
  • Subjects with the following abnormal laboratory values at screening as defined by the enhanced toxicity table: creatinine grade 2 or greater (>1.5 times [ULN]); \<10.0 grams per deciliter; thrombocytopenia grade 2 or greater (under 50 times 10\^9 cells per liter); serum potassium grade 2 or greater (\<3.0 milliequivalents per liter); grade 3 (>=3.0 times ULN); alanine aminotransferase grade 3 (>=3.0 times ULN); grade 3 (>=2.5 times ULN); international normalized ratio grade 3 (>=2.5 times ULN); total white cell count grade 3 (\<2.0 times 10\^9 cells per liter).
  • Subjects who are selected to undergo FDG-PET/CT who have been estimated to have been exposed to ionizing radiation in excess of 10 millisievert above background over the previous three-year period as a result of occupational exposure to radiation or as a result of research studies. This will be judged through clinical history taking.
  • Women who are susceptible to heavy periods or heavy vaginal bleeding or spotting will be excluded in order to minimize blood loss and avoid confounding effects on the interpretation of hematology parameters.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    Rifafour e-275

    All participants will receive a standard-of-care therapy (rifafour e-275) tablet, orally, once daily from Day 1 to Day 14. Participants will receive the standard treatment for tuberculosis (i.e. rifafour e-275 or equivalent generic alternative) once the study treatment (Day 1 to Day 14) is completed.

    Drug: Rifafour e-275

  • Experimental
    GSK3036656 1 mg

    Participants will receive a loading dose of GSK3036656 3 milligram (mg), capsule, orally on Day 1, followed by maintenance dose of GSK3036656 1 mg, orally, once daily from Day 2 to Day 14.

    Drug: GSK3036656

  • Experimental
    GSK3036656 5 mg

    Participants will receive a loading dose of GSK3036656 15 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 5 mg, orally, once daily from Day 2 to Day 14.

    Drug: GSK3036656

  • Experimental
    GSK3036656 15 mg

    Participants will receive a loading dose of GSK3036656 30 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 15 mg, orally, once daily from Day 2 to Day 14.

    Drug: GSK3036656

  • Experimental
    GSK3036656 30 mg

    Participants will receive a loading dose of GSK3036656 75 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 30 mg, orally, once daily from Day 2 to Day 14.

    Drug: GSK3036656

Interventions

07

What researchers measure

Primary outcomes

  1. Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14

    The Early Bactericidal Activity was determined by change in log10CFU/mL of sputum over the period Baseline to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

    Time frame: Baseline and up to Day 14

Secondary outcomes

  1. Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2

    The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Baseline to Day 2. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

    Time frame: Baseline and up to Day 2

  2. Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14

    The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Day 2 to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate.

    Time frame: Day 2 to Day 14

  3. Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14

    The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 14. The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

    Time frame: Baseline and up to Day 14

  4. Change in log10 TTP From Baseline to Day 2

    The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 2. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

    Time frame: Baseline and up to Day 2

  5. Change in log10 TTP From Day 2 to Day 14

    The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Day 2 to Day 14. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube.

    Time frame: Day 2 to Day 14

  6. Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3036656.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14

  7. Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656

    Blood samples were collected at indicated time points for PK analysis of GSK3036656.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14

  8. Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656

    Blood samples were collected at indicated time points for PK analysis of GSK3036656.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14

  9. Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656

    Blood samples were collected at indicated time points for PK analysis of GSK3036656.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14

  10. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.

    Time frame: Up to Day 28 (follow-up visit)

  11. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils, and platelet count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  12. Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  13. Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  14. Change From Baseline in Hematology Parameter: Red Blood Cells Count

    Blood samples were collected to analyze the hematology parameter: red blood cells count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  15. Change From Baseline in Hematology Parameter: Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: mean corpuscular volume. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  16. Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin

    Blood samples were collected to analyze the hematology parameter: mean corpuscle hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  17. Change From Baseline in Hematology Parameter: Reticulocytes

    Blood samples were collected to analyze the hematology parameter: reticulocytes. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  18. Change From Baseline in Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, calcium, chloride, potassium, sodium, and blood urea nitrogen. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  19. Change From Baseline in Chemistry Parameters: Lactate Dehydrogenase (LDH), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT)

    Blood samples were collected to analyze the chemistry parameters: LDH, ALT, ALP, AST and GGT. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  20. Change From Baseline in Chemistry Parameters: Creatinine, Indirect Bilirubin, Direct Bilirubin and Total Bilirubin

    Blood samples were collected to analyze the chemistry parameters: creatinine, indirect bilirubin, direct bilirubin and total bilirubin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  21. Change From Baseline in Chemistry Parameter: Total Protein

    Blood samples were collected to analyze the chemistry parameter: total protein. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

  22. Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

    Urine samples were collected to assess urine occult blood and urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased and increase to abnormal for urine occult blood and protein indicating proportional concentrations in the urine sample. 'No change/decreased' means no change from Baseline or a value less than the Baseline value. 'Increase to abnormal' means an increase from the Baseline value that is considered as an abnormal value. Baseline value is the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline (Day 1, Pre-dose) and up to Day 28 (follow-up visit)

  23. Number of Participants With Worst Case Vital Sign Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

    Vital signs were measured in a semi-supine or supine position after 5 minutes rest. The PCI range for vital signs were: systolic blood pressure (SBP) (lower: \<85 and upper: \>160 milliliter of mercury \[mmHg\]); diastolic blood pressure (DBP) (lower: \<45 and upper: \>100 mmHg); heart rate (lower: \<40 and upper: \>110 beats per minute \[bpm\]); respiratory rate (lower: 10 and upper: 28 breaths per minutes) and temperature (lower: \<35 and upper: \>37.9 degrees Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Participants were counted twice if the participant had values that changed "To Low" and "To High".

    Time frame: Up to Day 28 (follow-up visit)

  24. Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings

    Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, uncorrected QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented.

    Time frame: Up to Day 28 (follow-up visit)

  25. Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)

    Twelve-lead ECGs were obtained to QTcF Interval and measured QT duration corrected for heart rate by Fridericia's formula interval. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits and the mean of the triplicate measurements at any given time point was used as the value for that time point. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

    Time frame: Baseline (Day 1, Pre-dose) and at Day 14

08

Results

Posted Oct 26, 2023

Participant flow

This was an open-label trial to investigate the early bactericidal activity, safety and tolerability of GSK3036656 in participants with drug-sensitive pulmonary tuberculosis. Participants received Rifafour e-275 as a standard-of-care or GSK3036656. Rifafour e-275 is a registered trademark of Sanofi-Aventis company.

Participant flow — Overall Study
MilestoneRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Started189171616
Safety population consisted of all randomized participants who received at least 1 dose of treatment189171615
Completed188151513
Not completed01213
Withdrew: Investigator discretion00100
Withdrew: Withdrawal by subject01112
Withdrew: Randomized, but did not receive treatment00001

Outcome measures

PrimaryChange in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14

The Early Bactericidal Activity was determined by change in log10CFU/mL of sputum over the period Baseline to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

Time frame:
Baseline and up to Day 14
Reported as:
Mean · Log10CFU/mL
Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14
Log10CFU/mLRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14-0.199 ± 0.0130-0.017 ± 0.0182-0.092 ± 0.0136-0.092 ± 0.0142-0.138 ± 0.0147
SecondaryChange in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2

The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Baseline to Day 2. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

Time frame:
Baseline and up to Day 2
Reported as:
Mean · log10CFU/mL
Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2
log10CFU/mLRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2-0.598 ± 0.08010.250 ± 0.1077-0.153 ± 0.0801-0.055 ± 0.0832-0.040 ± 0.0855
SecondaryChange in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14

The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Day 2 to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate.

Time frame:
Day 2 to Day 14
Reported as:
Mean · log10CFU/mL
Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14
log10CFU/mLRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14-0.162 ± 0.0169-0.037 ± 0.0233-0.080 ± 0.0173-0.086 ± 0.0181-0.129 ± 0.0192
SecondaryChange in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14

The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 14. The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

Time frame:
Baseline and up to Day 14
Reported as:
Mean · log10hours
Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14
log10hoursRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 140.025 ± 0.00100.000 ± 0.00150.015 ± 0.00110.021 ± 0.00120.022 ± 0.0013
SecondaryChange in log10 TTP From Baseline to Day 2

The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 2. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.

Time frame:
Baseline and up to Day 2
Reported as:
Mean · log10hours
Change in log10 TTP From Baseline to Day 2
log10hoursRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 TTP From Baseline to Day 20.105 ± 0.0068-0.003 ± 0.00960.021 ± 0.00710.032 ± 0.00720.066 ± 0.0074
SecondaryChange in log10 TTP From Day 2 to Day 14

The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Day 2 to Day 14. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube.

Time frame:
Day 2 to Day 14
Reported as:
Mean · log10hours
Change in log10 TTP From Day 2 to Day 14
log10hoursRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change in log10 TTP From Day 2 to Day 140.017 ± 0.00110.001 ± 0.00160.013 ± 0.00120.017 ± 0.00120.016 ± 0.0013
SecondaryArea Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3036656.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656
Hours*nanogram per milliliterGSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656281.8 ± 25.71495.6 ± 12.54493.8 ± 12.511505.6 ± 17.9
SecondaryArea Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656

Blood samples were collected at indicated time points for PK analysis of GSK3036656.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656
Hours*nanogram per milliliterGSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656282.1 ± 25.81497.1 ± 12.44493.9 ± 12.511540.0 ± 17.8
SecondaryMaximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656

Blood samples were collected at indicated time points for PK analysis of GSK3036656.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656
Nanogram per milliliterGSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK303665616.93 ± 23.794.60 ± 24.7291.41 ± 18.9705.24 ± 20.2
SecondaryTime to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656

Blood samples were collected at indicated time points for PK analysis of GSK3036656.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Reported as:
Median · Hours
Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656
HoursGSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK30366561.500 (0.50 to 6.00)2.492 (0.50 to 4.00)1.000 (0.50 to 4.00)2.000 (0.50 to 8.00)
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.

Time frame:
Up to Day 28 (follow-up visit)
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
ParticipantsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Non-SAEs14714159
SAEs100000
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils, and platelet count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count
10^9 cells per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Basophils-0.006 ± 0.0281-0.009 ± 0.0242-0.018 ± 0.0248-0.003 ± 0.0263-0.005 ± 0.0267
Eosinophils0.086 ± 0.13830.075 ± 0.11350.088 ± 0.12390.072 ± 0.08800.057 ± 0.0642
Lymphocytes0.051 ± 0.3024-0.066 ± 0.30660.157 ± 0.40100.099 ± 0.51750.136 ± 0.3861
Monocytes-0.073 ± 0.3236-0.156 ± 0.1467-0.125 ± 0.1376-0.301 ± 0.3647-0.242 ± 0.2225
Total neutrophils-0.940 ± 1.9563-0.509 ± 0.9609-0.613 ± 1.4654-1.633 ± 1.6475-0.949 ± 1.2011
Platelet count-59.6 ± 105.19-35.0 ± 83.00-93.6 ± 81.05-7.3 ± 81.33-78.6 ± 43.53
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Grams per liter
Change From Baseline in Hematology Parameter: Hemoglobin
Grams per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Hemoglobin-3.4 ± 9.15-2.9 ± 6.640.0 ± 7.321.7 ± 9.21-4.6 ± 14.99
SecondaryChange From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Hematocrit-0.012 ± 0.0308-0.008 ± 0.02250.003 ± 0.02470.007 ± 0.0277-0.018 ± 0.0454
SecondaryChange From Baseline in Hematology Parameter: Red Blood Cells Count

Blood samples were collected to analyze the hematology parameter: red blood cells count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Hematology Parameter: Red Blood Cells Count
10^12 cells per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Red Blood Cells Count-0.130 ± 0.3067-0.091 ± 0.27760.016 ± 0.27530.059 ± 0.2875-0.216 ± 0.6590
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: mean corpuscular volume. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Femtoliter
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume
FemtoliterRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume0.2 ± 1.92-0.3 ± 0.890.1 ± 1.360.5 ± 0.920.0 ± 1.35
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin

Blood samples were collected to analyze the hematology parameter: mean corpuscle hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Picograms
Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin
PicogramsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin0.2 ± 0.65-0.1 ± 0.64-0.1 ± 0.640.1 ± 0.700.3 ± 0.75
SecondaryChange From Baseline in Hematology Parameter: Reticulocytes

Blood samples were collected to analyze the hematology parameter: reticulocytes. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Percentage of reticulocytes
Change From Baseline in Hematology Parameter: Reticulocytes
Percentage of reticulocytesRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Hematology Parameter: Reticulocytes0.0045 ± 0.005680.0035 ± 0.002450.0041 ± 0.002550.0055 ± 0.003740.0025 ± 0.00456
SecondaryChange From Baseline in Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, calcium, chloride, potassium, sodium, and blood urea nitrogen. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Millimoles per liter
Change From Baseline in Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Glucose-0.29 ± 0.7340.05 ± 0.8090.17 ± 1.047-0.30 ± 0.902-0.86 ± 1.477
Calcium0.021 ± 0.0814-0.018 ± 0.1007-0.034 ± 0.06720.005 ± 0.0633-0.024 ± 0.0860
Chloride1.1 ± 2.141.0 ± 1.691.6 ± 2.592.3 ± 2.252.3 ± 3.79
Potassium-0.39 ± 0.398-0.79 ± 0.925-0.47 ± 0.403-0.15 ± 0.521-0.28 ± 0.521
Sodium0.4 ± 2.331.0 ± 1.600.7 ± 2.552.1 ± 3.490.5 ± 3.10
Blood urea nitrogen-0.054 ± 0.3207-0.169 ± 0.54930.125 ± 0.30740.145 ± 0.28600.042 ± 0.3198
SecondaryChange From Baseline in Chemistry Parameters: Lactate Dehydrogenase (LDH), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT)

Blood samples were collected to analyze the chemistry parameters: LDH, ALT, ALP, AST and GGT. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · International units per liter
Change From Baseline in Chemistry Parameters: Lactate Dehydrogenase (LDH), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT)
International units per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
LDH-56.3 ± 57.81-52.8 ± 72.99-18.3 ± 36.22-26.5 ± 57.92-8.5 ± 73.83
ALT-20.6 ± 35.79-37.0 ± 62.35-8.1 ± 18.22-11.0 ± 18.605.9 ± 20.77
ALP-3.1 ± 21.22-34.1 ± 61.88-16.8 ± 32.52-4.0 ± 70.73-7.5 ± 13.06
AST-13.7 ± 22.27-12.9 ± 13.94-5.6 ± 9.86-8.4 ± 13.472.2 ± 8.74
GGT-3.9 ± 22.20-51.0 ± 76.64-14.9 ± 28.18-16.4 ± 30.83-5.2 ± 23.23
SecondaryChange From Baseline in Chemistry Parameters: Creatinine, Indirect Bilirubin, Direct Bilirubin and Total Bilirubin

Blood samples were collected to analyze the chemistry parameters: creatinine, indirect bilirubin, direct bilirubin and total bilirubin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Micromoles per liter
Change From Baseline in Chemistry Parameters: Creatinine, Indirect Bilirubin, Direct Bilirubin and Total Bilirubin
Micromoles per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Creatinine0.6 ± 6.092.8 ± 4.743.1 ± 9.131.5 ± 6.240.6 ± 5.08
Indirect bilirubin-1.2 ± 1.08-0.9 ± 1.07-0.1 ± 1.51-1.1 ± 1.710.3 ± 1.03
Direct bilirubin-0.6 ± 0.70-0.5 ± 1.070.0 ± 0.76-0.7 ± 0.90-0.7 ± 1.38
Total bilirubin-1.5 ± 1.34-1.1 ± 1.81-0.1 ± 1.51-1.7 ± 2.050.0 ± 1.58
SecondaryChange From Baseline in Chemistry Parameter: Total Protein

Blood samples were collected to analyze the chemistry parameter: total protein. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Grams per liter
Change From Baseline in Chemistry Parameter: Total Protein
Grams per literRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in Chemistry Parameter: Total Protein-1.7 ± 3.72-1.0 ± 6.46-1.3 ± 4.732.2 ± 6.73-4.2 ± 5.83
SecondaryNumber of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

Urine samples were collected to assess urine occult blood and urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased and increase to abnormal for urine occult blood and protein indicating proportional concentrations in the urine sample. 'No change/decreased' means no change from Baseline or a value less than the Baseline value. 'Increase to abnormal' means an increase from the Baseline value that is considered as an abnormal value. Baseline value is the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline (Day 1, Pre-dose) and up to Day 28 (follow-up visit)
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
ParticipantsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Occult blood: No change/decrease15916149
Occult blood: Increase to abnormal30126
Protein: No change/decrease859109
Protein: Increase to abnormal104866
SecondaryNumber of Participants With Worst Case Vital Sign Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

Vital signs were measured in a semi-supine or supine position after 5 minutes rest. The PCI range for vital signs were: systolic blood pressure (SBP) (lower: \<85 and upper: \>160 milliliter of mercury \[mmHg\]); diastolic blood pressure (DBP) (lower: \<45 and upper: \>100 mmHg); heart rate (lower: \<40 and upper: \>110 beats per minute \[bpm\]); respiratory rate (lower: 10 and upper: 28 breaths per minutes) and temperature (lower: \<35 and upper: \>37.9 degrees Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Participants were counted twice if the participant had values that changed "To Low" and "To High".

Time frame:
Up to Day 28 (follow-up visit)
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Vital Sign Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
ParticipantsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
SBP: To low11010
SBP: To within Range or No Change178171515
SBP: To High00000
DBP: To low11100
DBP: To within Range or No Change167161615
DBP: To High11000
Heart rate: To low00000
Heart rate: To within Range or No Change166151515
Heart rate: To High23210
Respiratory rate: To low00000
Respiratory rate: To within Range or No Change189171315
Respiratory rate: To High00030
Temperature: To low00010
Temperature: To within Range or No Change177161415
Temperature: To High12110
SecondaryNumber of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings

Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, uncorrected QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented.

Time frame:
Up to Day 28 (follow-up visit)
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings
ParticipantsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Abnormal, not clinically significant135121210
Abnormal - clinically significant00010
SecondaryChange From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)

Twelve-lead ECGs were obtained to QTcF Interval and measured QT duration corrected for heart rate by Fridericia's formula interval. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits and the mean of the triplicate measurements at any given time point was used as the value for that time point. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.

Time frame:
Baseline (Day 1, Pre-dose) and at Day 14
Reported as:
Mean · Milliseconds
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)
MillisecondsRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)6.4 ± 13.6411.3 ± 14.40-1.8 ± 20.489.5 ± 14.914.0 ± 16.76

Adverse events

Collected over All-cause mortality, SAEs and non-SAEs were collected up to Day 28 (follow-up visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifafour e-2750/18 (0%)0/18 (0%)14/18 (77.8%)
GSK3036656 1 mg0/9 (0%)0/9 (0%)7/9 (77.8%)
GSK3036656 5 mg0/17 (0%)0/17 (0%)14/17 (82.4%)
GSK3036656 15 mg0/16 (0%)0/16 (0%)15/16 (93.8%)
GSK3036656 30 mg0/15 (0%)0/15 (0%)9/15 (60%)
Most frequent other events
Showing 10 of 58
Most frequent other events
EventRifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mg
HaemoptysisRespiratory, thoracic and mediastinal disorders2/180/95/172/161/15
PruritusSkin and subcutaneous tissue disorders2/182/91/174/160/15
ArthralgiaMusculoskeletal and connective tissue disorders2/180/91/174/160/15
HeadacheNervous system disorders3/182/91/172/161/15
Abdominal painGastrointestinal disorders3/180/90/170/162/15
VomitingGastrointestinal disorders0/180/91/171/162/15
NauseaGastrointestinal disorders2/180/90/172/160/15
Rash papularSkin and subcutaneous tissue disorders1/180/90/172/160/15
MyalgiaMusculoskeletal and connective tissue disorders1/181/90/172/160/15
DiarrhoeaGastrointestinal disorders1/180/92/170/160/15

Baseline characteristics

Safety Population consisted of all randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)Rifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mgTotal
Mean37.0 ± 10.2037.8 ± 8.3838.1 ± 10.3339.8 ± 12.3338.5 ± 9.8238.2 ± 10.22
Sex: Female, Male
Sex: Female, Male(Participants)Rifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mgTotal
Female000000
Male18917161575
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rifafour e-275GSK3036656 1 mgGSK3036656 5 mgGSK3036656 15 mgGSK3036656 30 mgTotal
Black or African American18917161575
09

Study locations

1 site
  • GSK Investigational Site
    Cape Town, 7530, South Africa
10

References and documents

Publications

  • Volynets GP, Usenko MO, Gudzera OI, Starosyla SA, Balanda AO, Syniugin AR, Gorbatiuk OB, Prykhod'ko AO, Bdzhola VG, Yarmoluk SM, Tukalo MA. Identification of dual-targeted Mycobacterium tuberculosis aminoacyl-tRNA synthetase inhibitors using machine learning. Future Med Chem. 2022 Sep;14(17):1223-1237. doi: 10.4155/fmc-2022-0085. Epub 2022 Jul 25. PubMed 35876255 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Dec 2021, 32 months.

Results were first posted in Oct 2023, 1 year 10 months after primary completion.

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2018
First posted
Jun 15, 2018
StartActual
Mar 22, 2019
Primary completionActual
Dec 3, 2021
CompletionActual
Dec 14, 2021
Results first posted
Oct 26, 2023
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03557281
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Mar 22, 2019
Primary completion
Dec 3, 2021
Completion
Dec 14, 2021
Results posted
Oct 26, 2023
Last update
Oct 26, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK656

Start the discussion